LifeScan Inc.

LifeScan Inc. is a diagnostic systems manufacturer specializing in blood glucose monitoring systems and diabetes management solutions. Founded in 1981, LifeScan is headquartered in Malvern, Pennsylvania, with a co-headquarters in Zug, Switzerland. The company operates as a private entity, having been acquired by Platinum Equity from Johnson & Johnson in October 2018 for approximately $2.1 billion. LifeScan has approximately 2,000 to 2,500 employees globally. In 2017, prior to its acquisition by Platinum Equity, LifeScan reported net revenue of approximately $1.5 billion. In July 2025, LifeScan Global Corporation filed for Chapter 11 bankruptcy protection and emerged in December 2025 with new majority ownership by Canyon Partners and Brigade Capital Management.

LifeScan's primary offerings include its OneTouch® brand of blood glucose meters, testing strips, lancets, and integrated digital health platforms. These products are designed for both home use and point-of-care testing in clinical settings. The company aims to provide patient-centric solutions that emphasize simplicity, accuracy, and accessibility in diabetes management. LifeScan also engages in partnerships to expand into continuous glucose monitoring (CGM) and digital therapeutics.

LifeScan Inc. is currently a defendant in one tracked patent litigation case, Cellspinsoft Inc. v. LifeScan Inc., filed in the Eastern District of Texas. This indicates a posture of an operating company defending against patent infringement assertions. The Eastern District of Texas is a known venue for patent litigation due to its history of favorable rulings for plaintiffs.

The single tracked case, Cellspinsoft Inc. v. LifeScan Inc., was filed on April 29, 2024. This case reflects LifeScan's involvement in defending its operations in the medical device and digital health technology space.